🇺🇸 FDA
Pipeline program

-, Sodium butyrate 1,1 g/L sol prep

RCAPHM18_0018

Phase 3 small_molecule active

Quick answer

-, Sodium butyrate 1,1 g/L sol prep for Hirschsprung's disease is a Phase 3 program (small_molecule) at ISTA Pharma Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
ISTA Pharma Limited
Indication
Hirschsprung's disease
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials